Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane
September 11, 2019 at 04:00 AM EDT
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation.